ScripThe year 2025 is set top be a pivotal one for the biopharma industry, marked by significant political changes in the US and beyond. Around half the world’s population live in countries that held natio
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S
ScripThe positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp
ScripConditions look ripe for an uptick in M&A this year after a fairly quiet 2022, while other types of strategic deals are also expected to increase in the face of a challenging funding situation for bio